Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure.
We characterized the raltegravir (RAL) susceptibility and the integrase (IN)-mediated replication capacity (RC) of RAL-resistant human immunodeficiency virus type 1 from two patients experiencing virologic failure during continuous RAL salvage therapy. The following two distinct outcomes were observed: (i) the selective outgrowth of virus with high-level RAL resistance and high IN-mediated RC leading to significant viral load rebound and (ii) the selection of virus with a slight reduction in RAL susceptibility and low IN-mediated RC resulting in sustained low-level viremia.
Fransen
Signe
S
Monogram Biosciences, South San Francisco, California, USA.
Karmochkine
Marina
M
Huang
Wei
W
Weiss
Laurence
L
Petropoulos
Christos J
CJ
Charpentier
Charlotte
C
D002460:Cell Line; D024882:Drug Resistance, Viral / Q000235:genetics; D019428:HIV Integrase Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D011760:Pyrrolidinones / Q000494:pharmacology*; D000068898:Raltegravir Potassium; D014779:Virus Replication / Q000187:drug effects
D019428:HIV Integrase Inhibitors; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium